BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$70.11 USD
+0.64 (0.92%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.13 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
BMRN 70.11 +0.64(0.92%)
Will BMRN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMRN
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Options Traders Know Something About BioMarin (BMRN) Stock We Don't?
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
BMRN or MYGN: Which Is the Better Value Stock Right Now?
Other News for BMRN
How Is The Market Feeling About Biomarin Pharmaceutical?
BioMarin's vosoritide granted orphan status for short stature in Noonan syndrome
Stifel Nicolaus Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Nike upgraded, PayPal downgraded: Wall Street's top analyst calls
BioMarin reinstated with an Outperform at Raymond James